SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has closed the transaction to acquire assets of Novan, Inc. (“Novan”) following the offer it made on July 17, 2023. On July 17, 2023, Ligand offered $15 million to acquire all of the assets of Novan as well as to provide up to $15 million in debtor-in-possession (“DIP”) financing.

圣地亚哥-（BUSINESS WIRE）-配体制药公司（纳斯达克股票代码：LGND）宣布，在2023年7月17日提出报价后，已结束收购Novan，Inc.（“Novan”）资产的交易。2023年7月17日，Ligand提供1500万美元收购Novan的所有资产，并提供高达1500万美元的现有纳税人（“DIP”）融资。

In September 2023, the Bankruptcy Court approved a $12.2 million bid from Ligand to purchase berdazimer gel and all the assets related to the NITRICIL™ technology platform, and the rights to the Bayer-partnered Sitavig program. The remaining commercial assets of EPI Health will be sold to other parties.

2023年9月，破产法院批准Ligand以1220万美元的出价购买berdazimer gel以及与NITRICIL相关的所有资产™ 技术平台以及拜耳合作的Sitavig计划的权利。EPI Health的剩余商业资产将出售给其他方。

The approved $12.2 million bid was credited to the $15 million DIP financing, with the balance of $2.8 million and accrued interest repaid to Ligand. Berdazimer gel remains on track for a PDUFA goal date of January 5, 2024, as the first potential at-home treatment for molluscum contagiosum..

批准的1220万美元出价归功于1500万美元的DIP融资，余额为280万美元，应计利息偿还给配体。Berdazimer凝胶仍在进行PDUFA目标日期2024年1月5日的跟踪，作为传染性软体动物的第一个潜在的家庭治疗方法。。

“We are pleased with the outcome of the bankruptcy proceeding resulting in Ligand’s full ownership of berdazimer gel, NITRICIL platform and related assets. We will look forward to the FDA’s decision regarding the New Drug Application for berdazimer gel in January of next year, and remain confident in its potential approval as the first-ever at home treatment for molluscum contagiosum,” said Todd Davis, CEO of Ligand.

“我们对破产程序的结果感到满意，导致Ligand完全拥有berdazimer gel，NITRICIL平台和相关资产。我们将期待FDA于明年1月决定申请berdazimer gel新药，并对其作为传染性软体动物首次在家治疗的潜在批准充满信心。”Ligand首席执行官托德·戴维斯说。

“We are ideally positioned to take advantage of special situations such as this, and, consistent with our business model, will seek marketing partners for the acquired assets to maximize value to Ligand shareholders.”.

“我们处于充分利用此类特殊情况的理想位置，并且与我们的商业模式一致，将寻求收购资产的营销合作伙伴，以最大限度地为配体股东创造价值。”。

Birch Lake acted as financial advisor and Morgan Lewis acted as legal advisor to Ligand for this transaction.

Birch Lake担任财务顾问，Morgan Lewis担任此次交易配体的法律顾问。

About Ligand Pharmaceuticals

关于配体药物

Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model generates value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure.

Ligand是一家生物制药公司，通过支持高价值药物的临床开发，实现科学进步。配体通过提供融资，许可我们的技术或两者来做到这一点。我们的商业模式通过创建由高效和低企业成本结构支持的生物技术和药品收入流多样化组合，为股东创造价值。

Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights and licensing our technology to help partners discover and develop medicines.

我们的目标是为投资者提供机会，以有利可图和多元化的方式参与生物技术行业的承诺。我们的商业模式基于中后期药物开发的资助计划，以换取经济权利并授权我们的技术帮助合作伙伴发现和开发药物。

We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs.

我们与其他制药公司合作，充分利用他们做得最好的（后期开发，监管管理和商业化），以创造我们的收入。我们的Captisol®平台技术是一种化学改性的环糊精，其结构旨在优化药物的溶解度和稳定性。

We have established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com..

我们与世界领先的制药公司建立了多个联盟，许可证和其他商业关系，包括安进，默克，辉瑞，爵士，武田，吉利德科学和百特国际。欲了解更多信息，请访问www.ligand.com。。

Follow Ligand on X (f/k/a Twitter) @Ligand_LGND.

遵循X上的配体（f/k/a Twitter）@Ligand_LGND。

We use X and our investor relations website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our X account and our website, in addition to following our press releases, SEC filings, public conference calls and webcasts..

我们使用X和我们的投资者关系网站作为披露材料非公开信息和遵守我们在FD法规下的披露义务的手段。除了关注我们的新闻稿，SEC文件，公开电话会议和网络广播之外，投资者还应该监控我们的X帐户和我们的网站。。

Forward-Looking Statements

前瞻性声明

This news release contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand's judgment as of the date of this release. Words such as “plans,” “believes,” “expects,” “anticipates,” and “will,” and similar expressions, are intended to identify forward-looking statements.

本新闻稿包含配体的前瞻性陈述，涉及风险和不确定性，并反映配体在本版发布之日的判断。诸如“计划”，“相信”，“期望”，“预期”和“意愿”之类的词语以及类似的表达方式旨在确定前瞻性陈述。

These forward-looking statements include: the timing and outcome of FDA review of Novan’s NDA related to berdazimer gel for the treatment of molluscum contagiosum infections or any of the products related to the NITRICIL™ technology platform; and the potential value of any of the assets acquired from Novan’s.

这些前瞻性声明包括：FDA审查与berdazimer凝胶相关的Novan NDA治疗传染性软体动物感染或任何与腈类有关的产品的时间和结果™ 技术平台；以及从Novan收购的任何资产的潜在价值。

Actual events or results may differ from Ligand’s or its partner’s expectations due to risks and uncertainties inherent in Ligand’s and its partner’s business, including, without limitation: the FDA may not approve berdazimer gel for the treatment of molluscum contagiosum infections; Ligand may not be successful in finding partners for the acquired assets, even if successful, may not achieve the anticipated benefits of such acquisition; and other risks described in Ligand’s and Novan’s prior press releases and filings with the Securities and Exchange Commission available at www.sec.gov.

由于配体及其合作伙伴业务固有的风险和不确定性，实际事件或结果可能与配体或其合作伙伴的预期不同，包括但不限于：FDA可能不批准用于治疗传染性软体动物感染的berdazimer凝胶；配体可能无法成功找到收购资产的合作伙伴，即使成功，也可能无法实现此类收购的预期收益；Ligand和Novan先前的新闻稿和美国证券交易委员会的文件中描述的其他风险，请访问www.sec.gov。

Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995..

配体在此版本发布之日以后不承担更新这些前瞻性声明的任何意图或义务。这种谨慎是根据1995年“私人证券诉讼改革法”的安全港规定作出的。。